liarozole has been researched along with Carcinoma, Epidermoid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borgers, M; Coene, MC; Daneels, G; De Coster, R; Moeremans, M; Ramaekers, FC; Schalken, JA; Smets, G; Van Ginckel, R; Van Wauwe, J | 1 |
| Gooding, WE; Grandis, JR; Smith, DC; Suscovich, TJ; Trump, DL; Zeng, Q | 1 |
1 trial(s) available for liarozole and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
Topics: Actins; Antineoplastic Agents, Hormonal; Biomarkers; Carcinoma, Squamous Cell; DNA Primers; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Humans; Imidazoles; Mouth Mucosa; Mouth Neoplasms; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor alpha; Tretinoin; Up-Regulation | 2000 |
1 other study(ies) available for liarozole and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Imidazoles; Immunoblotting; Immunohistochemistry; Keratins; Male; Neoplasm Transplantation; Organ Size; Prostate; Prostatic Neoplasms; Random Allocation; Rats; Rats, Inbred F344; Tretinoin; Tumor Cells, Cultured; Vimentin | 1995 |